Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

chronic myelogenous leukemia, BCR-ABL1 positive - Clinical Profile, Treatments & Trials | Kisho | Kisho

Features include: Reduced leukocyte alkaline phosphatase, Ph-positive acute lymphoblastic leukemia, and Chronic myelogenous leukemia.

Organ System	Phenotype Count	Example Features
Blood and immune system	1	Reduced leukocyte alkaline phosphatase

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

9 FDA-approved treatments are available for chronic myelogenous leukemia, BCR-ABL1 positive, including NILOTINIB (TASIGNA, approved 2007), ASCIMINIB (SCEMBLIX, approved 2021), and IMATINIB MESYLATE (GLEEVEC, approved 2003). An additional 26 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status
NILOTINIB	NILOTINIB	—	2025	Available
DANZITEN	NILOTINIB	—	2024	Available
PHYRAGO	DASATINIB	—	2023	Available
BOSULIF	BOSUTINIB	—	2023	Available
CYCLOPHOSPHAMIDE	CYCLOPHOSPHAMIDE INJECTION, SOLUTION	—	2023	Available
FRINDOVYX	CYCLOPHOSPHAMIDE	—	2023	Available
SCEMBLIX	ASCIMINIB	—	2021	Available
SYNRIBO	—	—	2012	Available
TASIGNA	NILOTINIB	—	2007	Available
DASATINIB	DASATINIB	—	2006	Available
GLEEVEC	IMATINIB MESYLATE	—	2003	Available
BUSULFEX	BUSULFAN	—	1999	Available
MYLERAN	BUSULFAN	—	1954	Available

Orphan Drug Designations

The following drugs have received orphan drug designation from the FDA for chronic myelogenous leukemia, BCR-ABL1 positive. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
small molecule inhibitor of bcr-abl tyrosine kinase	small molecule inhibitor of bcr-abl tyrosine kinase	Enliven Therapeutics, Inc.	2024	—	Designated
Small molecule inhibitor of the bcr-abl tyrosine kinase	Small molecule inhibitor of the bcr-abl tyrosine kinase	Terns, Inc.	2024	—	Designated

Clinical Trials

173 trials found

Explore Trials

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

173 clinical trials registered, 61 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE4, 10 PHASE3, 69 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT02727803](https://clinicaltrials.gov/study/NCT02727803)	Personalized NK Cell Therapy in CBT	PHASE2	M.D. Anderson Cancer Center	RECRUITING
[NCT05805605](https://clinicaltrials.gov/study/NCT05805605)	Allo HSCT Using RIC and PTCy for Hematological Diseases	PHASE2	Masonic Cancer Center, University of Minnesota	RECRUITING
[NCT07020533](https://clinicaltrials.gov/study/NCT07020533)	A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant	PHASE1	City of Hope Medical Center	RECRUITING
[NCT01890486](https://clinicaltrials.gov/study/NCT01890486)	The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen	—	Wake Forest University Health Sciences	RECRUITING
[NCT07354074](https://clinicaltrials.gov/study/NCT07354074)	Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP	PHASE2	Novartis Pharmaceuticals	RECRUITING

13 publications have been identified in PubMed for chronic myelogenous leukemia, BCR-ABL1 positive. Research spans Review / Meta-Analysis (31%), Case Report / Case Series (31%), and Epidemiology / Natural History (15%).

Research Type	Count	% of Total
Research summaries	4	31%
Patient case studies	4	31%
Disease patterns and progression	2	15%
Other research	1	8%
Testing and diagnosis research	1	8%
Clinical study results	1

Recent Publications

Sato I (2026). [PMID: 41905906](https://pubmed.ncbi.nlm.nih.gov/41905906/). *Rinsho Ketsueki*. [Clinical Trial Publication]
Zou Y (2026). [PMID: 42402589](https://pubmed.ncbi.nlm.nih.gov/42402589/). *J Nanobiotechnology*. [Diagnostic / Biomarker]
Sun C (2026). [PMID: 42174991](https://pubmed.ncbi.nlm.nih.gov/42174991/). *Stud Health Technol Inform*. [Other]
Yokoyama S (2026). [PMID: 42020684](https://pubmed.ncbi.nlm.nih.gov/42020684/). *Int J Hematol*. [Epidemiology / Natural History]
Jajosky AN (2025). [PMID: 40371899](https://pubmed.ncbi.nlm.nih.gov/40371899/). *Haematologica*. [Review / Meta-Analysis]
Maher P (2025). [PMID: 40618562](https://pubmed.ncbi.nlm.nih.gov/40618562/). *Cancer Genet*. [Case Report / Case Series]
Sundaresan D (2025). [PMID: 38975676](https://pubmed.ncbi.nlm.nih.gov/38975676/). *Indian J Pathol Microbiol*. [Case Report / Case Series]
Dabrowski DS (2025). [PMID: 41063870](https://pubmed.ncbi.nlm.nih.gov/41063870/). *Case Rep Oncol*. [Case Report / Case Series]
Mughal TI (2025). [PMID: 39825826](https://pubmed.ncbi.nlm.nih.gov/39825826/). *Hematol Oncol*. [Review / Meta-Analysis]
Zhang X (2025). [PMID: 40779457](https://pubmed.ncbi.nlm.nih.gov/40779457/). *Clin Lab*. [Review / Meta-Analysis]

Kisho

chronic myelogenous leukemia, BCR-ABL1 positive

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Treatment

Approved Therapies

Orphan Drug Designations

Clinical Trials

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

chronic myelogenous leukemia, BCR-ABL1 positive

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Treatment

Approved Therapies

Orphan Drug Designations

Clinical Trials

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team